Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6597006 | 0.88 | PRKAG1 (0.50) | KDM4EALDH1A1HPGDPOLBHSD17B10 | |
| SCHEMBL6567169 | 0.88 | ALDH1A1 (0.52) | KDM4EALDH1A1HPGDPOLBF2 | |
| SCHEMBL6565865 | 0.81 | EGLN1 (0.57) | KDM4EALDH1A1HPGDPOLBSMN1; SMN2 | |
| SCHEMBL6564111 | 0.79 | MTNR1B (0.48) | KDM4EALDH1A1HPGDPOLBF2 | |
| SCHEMBL6564049 | 0.79 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDPOLBF2 | |
| SCHEMBL6086827 | 0.78 | NCF1 (0.51) | KDM4EALDH1A1HPGDPOLBF2 | |
| SCHEMBL8779126 | 0.77 | KDM4E (0.46) | KDM4EALDH1A1HPGDPOLBF2 | |
| SCHEMBL8006191 | 0.77 | NCF1 (0.50) | KDM4EALDH1A1HPGDPOLBF2 | |
| SCHEMBL20681140 | 0.76 | PIM1 (0.46) | KDM4EALDH1A1HPGDPOLBGLA | |
| SCHEMBL873205 | 0.76 | NCF1 (0.49) | KDM4EALDH1A1HPGDPOLBF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343516-A4 | ANALOGUES OF THIOCORALINE AND BE-22179 | SCRIPPS RESEARCH INST (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040072738-A1 | Analogues of thiocoraline and be-22179 | SCRIPPS RESEARCH INSTITUTE, THE | 2004-04-15 | — | — | US | disclosed |
| EP-0765871-B1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | FIBROGEN INC (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1343516-A2 | ANALOGUES OF THIOCORALINE AND BE-22179 | The Scripps Research Institute (US) | 2003-09-17 | — | — | EP | disclosed |
| CN-1120157-C | Substituted quinoline-2-carboxamides, process for their preparation and their use as pharmaceuticals, and intermediates thereof | FIBER GENE CORP (US) | 2003-09-03 | — | — | CN | disclosed |
| WO-2002049577-A2 | ANALOGUES OF THIOCORALINE AND BE-22179 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-06-27 | — | — | WO | disclosed |
| US-5726305-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-03-10 | — | — | US | disclosed |
| US-5719164-A | Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | disclosed |
| CN-1154365-A | Substituted quinoline-2-carboxamides, process for their preparation and their use as pharmaceuticals, and intermediates thereof | HOECHST AG (DE) | 1997-07-16 | — | — | CN | disclosed |
| EP-0765871-A1 | Substituted Quinoline-2-carboxamides, their preparation and their use as prolyle-4-hydroxylase Inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
| US-4780416-A | BACTERICIDES, ANTITUMOR AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-10-25 | — | — | US | disclosed |
| US-4631256-A | FROM ACTINOMYCIN-ANTIBIOTIC, ANTITUMOR AGENT | BRISTOL-MYERS COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| US-4599310-A | Process for producing antitumor antibiotic compound | BRISTOL-MYERS COMPANY (US) | 1986-07-08 | — | — | US | disclosed |
| US-4582639-A | SANDRAMYCIN | BRISTOL-MYERS COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| US-4451456-A | Antitumor antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072738-A1 | Analogues of thiocoraline and be-22179 | SSBP1, TOP2B, TOP1 | KDM4E 3356/4885ALDH1A1 3103/4885HPGD 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.